Navigation Links
Study projects 60 percent increase in ESRD population by 2020
Date:11/3/2007

Although estimates have been adjusted downward in light of the most recent data, researchers still predict sharp increases in the U.S. incidence and prevalence of end-stage renal disease (ESRD) in the years ahead, according to a paper being presented at the American Society of Nephrology's 40th Annual Meeting and Scientific Exposition in San Francisco.

"The expected number of patients with ESRD in 2020 is almost 785,000, which is an increase of over 60 percent compared to 2005," comments Dr. David T. Gilbertson of the U.S. Renal Data System (USRDS) and the Minneapolis Medical Research Foundation, Minneapolis, Minn. Using data available through 2005, the study updates previous estimates based on data through 2000.

The researchers used statistical techniques to project available data on the ESRD population to the year 2020. The model took into account a wide range of factors, including expected trends in population growth and the rising rate of diabetesthe main cause of kidney disease. The study also incorporated the latest data on the risk of progression to ESRD once kidney disease is present.

Based on the results, Dr. Gilbertson and colleagues predict that the U.S. incidence (number of new cases) of ESRD will be about 135,000 in 2015. This figure is about 3,000 lower than the previous estimate. For reasons that are not entirely clear, the incidence of ESRD has been decreasing in recent years, and the updated figure accounts for that trend. The predicted prevalence (total number of cases) of ESRD in 2015 is estimated at 680,000about 33,000 less than the previous estimate.

Nevertheless, based on a combination of trendsincluding the aging of the "Baby Boomer" population, rising diabetes rates, and improvements kidney disease treatment allowing better survivalthe authors project continued increases in numbers of Americans affected by ESRD. By 2020, the incidence (new cases) of ESRD is expected to rise to 151,000 per year (compared to 107,000 in 2005). Prevalence (all cases) is expected to increase to 785,000 (compared to 485,000 in 2005).

"These projections play an important role in shaping public health policy and health care planning related to the treatment of kidney disease," says Dr. Gilbertson. "Medicare pays for the care for the vast majority of patients with ESRD, with costs approaching $60,000 per year for every patient."

The predictions suggest that, despite recent declines in new cases, policymakers should account for continued increases in the health and economic impact of ESRD in the United States. "While relatively flat ESRD incidence rates may show some progress towards Healthy People 2010 goals of reducing ESRD incidence, it is important to know the expected future counts of patients, as opposed to rates, to inform public health policy and health care planning related to the treatment of kidney disease," Dr. Gilbertson says. "The financial and human resources that will be needed to care for these patients in 2020 will be considerable."


'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-558-8423
American Society of Nephrology
Source:Eurekalert

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... Dr. Farhan Qureshi is an esteemed dentist who offers a ... practice has two convenient office locations in Alexandria and Arlington, Virginia. Recently, Find Local ... Alexandria area. This award confirms the fact that Dr. Qureshi’s patients have left ...
(Date:1/18/2017)... ... 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), a ... Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. The ... thought leader interaction in, live video and interactive digital platforms. , In making ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... of the revolutionary Active Brake Technology (ABT), an innovative braking system that allows ... Active Brake Technology addresses one of the biggest concerns of beginner and intermediate ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s resolutions? ... the perfect time for a reset. The U.S. Apple Association agrees and recommends ... of the factors that contribute to heart disease. , The U.S. Apple Association – ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, but it ... Dentists have several general anesthesia alternatives and finding the right option can result in ... in Tokyo, Japan wanted to find out which anesthetic was the better choice in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... January 17, 2017 Management to Discuss ... Ltd.   KIT-302 Development On Track For An ... in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an ... Monday, January 23 rd at 8:30am Eastern Time to discuss the recent ...
(Date:1/17/2017)... , Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... patient has been enrolled in a Phase 3 clinical ... best supportive care (BSC) in the prevention of hepatic ... hematopoietic stem cell transplant (HSCT) who are at high ... The defibrotide clinical trial will be conducted across approximately ...
(Date:1/17/2017)... 2017  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, plans to announce ... 2016 after the market closes on Wednesday, February 1, ... p.m. ET that day to discuss those results. ... 407-8037 or (201) 689-8037.  For 72 hours following the ...
Breaking Medicine Technology: